IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0174513.html
   My bibliography  Save this article

Cost-effectiveness of a transitional pharmaceutical care program for patients discharged from the hospital

Author

Listed:
  • Fatma Karapinar-Çarkıt
  • Ronald van der Knaap
  • Fatiha Bouhannouch
  • Sander D Borgsteede
  • Marjo J A Janssen
  • Carl E H Siegert
  • Toine C G Egberts
  • Patricia M L A van den Bemt
  • Marieke F van Wier
  • Judith E Bosmans

Abstract

Background: To improve continuity of care at hospital admission and discharge and to decrease medication errors pharmaceutical care programs are developed. This study aims to determine the cost-effectiveness of the COACH program in comparison with usual care from a societal perspective. Methods: A controlled clinical trial was performed at the Internal Medicine department of a general teaching hospital. All admitted patients using at least one prescription drug were included. The COACH program consisted of medication reconciliation, patient counselling at discharge, and communication to healthcare providers in primary care. The primary outcome was the proportion of patients with an unplanned rehospitalisation within three months after discharge. Also, the number of quality-adjusted life-years (QALYs) was assessed. Cost data were collected using cost diaries. Uncertainty surrounding cost differences and incremental cost-effectiveness ratios between the groups was estimated by bootstrapping. Results: In the COACH program, 168 patients were included and in usual care 151 patients. There was no significant difference in the proportion of patients with unplanned rehospitalisations (mean difference 0.17%, 95% CI -8.85;8.51), and in QALYs (mean difference -0.0085, 95% CI -0.0170;0.0001). Total costs for the COACH program were non-significantly lower than usual care (-€1160, 95% CI -3168;847). Cost-effectiveness planes showed that the program was not cost-effective compared with usual care for unplanned rehospitalisations and QALYs gained. Conclusion: The COACH program was not cost-effective in comparison with usual care. Future studies should focus on high risk patients and include other outcomes (e.g. adverse drug events) as this may increase the chances of a cost-effective intervention.

Suggested Citation

  • Fatma Karapinar-Çarkıt & Ronald van der Knaap & Fatiha Bouhannouch & Sander D Borgsteede & Marjo J A Janssen & Carl E H Siegert & Toine C G Egberts & Patricia M L A van den Bemt & Marieke F van Wier &, 2017. "Cost-effectiveness of a transitional pharmaceutical care program for patients discharged from the hospital," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-20, April.
    • Handle: RePEc:plo:pone00:0174513
    DOI: 10.1371/journal.pone.0174513
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0174513
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0174513&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0174513?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Rachel Elliott & Koen Putman & James Davies & Lieven Annemans, 2014. "A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions," PharmacoEconomics, Springer, vol. 32(12), pages 1185-1199, December.
    2. Judith Bosmans & Oscar Brook & Hein Hout & Martine Bruijne & Hugo Nieuwenhuyse & Lex Bouter & Wim Stalman & Maurits Tulder, 2007. "Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants," PharmacoEconomics, Springer, vol. 25(1), pages 25-37, January.
    3. William C. Black, 1990. "The CE Plane," Medical Decision Making, , vol. 10(3), pages 212-214, August.
    4. Jan B. Oostenbrink & Maiwenn J. Al, 2005. "The analysis of incomplete cost data due to dropout," Health Economics, John Wiley & Sons, Ltd., vol. 14(8), pages 763-776, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mohamed El Alili & Johanna M. van Dongen & Jonas L. Esser & Martijn W. Heymans & Maurits W. van Tulder & Judith E. Bosmans, 2022. "A scoping review of statistical methods for trial‐based economic evaluations: The current state of play," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2680-2699, December.
    2. Judith Bosmans & Oscar Brook & Hein Hout & Martine Bruijne & Hugo Nieuwenhuyse & Lex Bouter & Wim Stalman & Maurits Tulder, 2007. "Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants," PharmacoEconomics, Springer, vol. 25(1), pages 25-37, January.
    3. Andrea Gabrio & Catrin Plumpton & Sube Banerjee & Baptiste Leurent, 2022. "Linear mixed models to handle missing at random data in trial‐based economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 31(6), pages 1276-1287, June.
    4. M. Carreras & M. García-Goñi & P. Ibern & J. Coderch & L. Vall-Llosera & J. Inoriza, 2011. "Estimates of patient costs related with population morbidity: can indirect costs affect the results?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(4), pages 289-295, August.
    5. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
    6. Jack Dowie, 2004. "Why cost‐effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 453-459, May.
    7. Elisa Sicuri & Silke Fernandes & Eusebio Macete & Raquel González & Ghyslain Mombo-Ngoma & Achille Massougbodgi & Salim Abdulla & August Kuwawenaruwa & Abraham Katana & Meghna Desai & Michel Cot & Mic, 2015. "Economic Evaluation of an Alternative Drug to Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-23, April.
    8. David K. Blough & Scott Ramsey & Sean D. Sullivan & Roger Yusen, 2009. "The impact of using different imputation methods for missing quality of life scores on the estimation of the cost‐effectiveness of lung‐volume‐reduction surgery," Health Economics, John Wiley & Sons, Ltd., vol. 18(1), pages 91-101, January.
    9. M. Carreras & Manuel García-Goñi & Pere Ibern & J. Coderch & L. Vall-Llosera & José María Inoriza, 2009. "Estimates of patient costs related with population morbidity: Can indirect costs affect the results?," Economics Working Papers 1138, Department of Economics and Business, Universitat Pompeu Fabra.
    10. Nadia Yakhelef & Martine Audibert & Gabriella Ferlazzo & Joseph Sitienei & Steve Wanjala & Francis Varaine & Maryline Bonnet & Helena Huerga, 2020. "Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis," Post-Print halshs-03170014, HAL.
    11. Perraudin, Clémence & Bugnon, Olivier & Pelletier-Fleury, Nathalie, 2016. "Expanding professional pharmacy services in European community setting: Is it cost-effective? A systematic review for health policy considerations," Health Policy, Elsevier, vol. 120(12), pages 1350-1362.
    12. Taehwan Park & Hyemin Kim & Seunghyun Song & Scott K. Griggs, 2022. "Economic Evaluation of Pharmacist-Led Digital Health Interventions: A Systematic Review," IJERPH, MDPI, vol. 19(19), pages 1-16, September.
    13. Adrian Gheorghe & Tracy E Roberts & Thomas D Pinkney & David C Bartlett & Dion Morton & Melanie Calvert & on behalf of the West Midlands Research Collaborative and the ROSSINI Trial Investigators, 2014. "The Cost-Effectiveness of Wound-Edge Protection Devices Compared to Standard Care in Reducing Surgical Site Infection after Laparotomy: An Economic Evaluation alongside the ROSSINI Trial," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-8, April.
    14. Keith Tolley;Gareth Morgan;Ray Cartwright;Rhys Williams, 1998. "Economic Aspects of Non-Hodgkin's Lymphoma," Series on Health 000436, Office of Health Economics.
    15. Ghislaine van Mastrigt & Caroline van Heugten & Anne Visser-Meily & Leonarda Bremmers & Silvia Evers, 2022. "Estimating the Burden of Stroke: Two-Year Societal Costs and Generic Health-Related Quality of Life of the Restore4Stroke Cohort," IJERPH, MDPI, vol. 19(17), pages 1-15, September.
    16. Rita Faria & Manuel Gomes & David Epstein & Ian White, 2014. "A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials," PharmacoEconomics, Springer, vol. 32(12), pages 1157-1170, December.
    17. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
    18. Lemoine, Coralie & Loubière, Sandrine & Boucekine, Mohamed & Girard, Vincent & Tinland, Aurélie & Auquier, Pascal, 2021. "Cost-effectiveness analysis of housing first intervention with an independent housing and team support for homeless people with severe mental illness: A Markov model informed by a randomized controlle," Social Science & Medicine, Elsevier, vol. 272(C).
    19. Briggs, Andrew & Tambour, Magnus, 1998. "The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions," SSE/EFI Working Paper Series in Economics and Finance 234, Stockholm School of Economics.
    20. Nadia YAKHELEF & Martine AUDIBERT & Bruno PEIRERA & Antoine MONS & Emmanuel CHABERT, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers 201534, CERDI.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0174513. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.